GlobeNewswire

IPsoft Equips Businesses to Accelerate Digital Transformation at Scale by Automating Delivery of Enterprise Services with 1Desk(TM)

Dela

1Desk(TM), the world's first AI platform to combine cognitive and autonomic technologies, will fully automate shared enterprise services

NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leader in enterprise AI, today announced its visionary new platform for business users, 1Desk(TM), that enables businesses to accelerate digital transformation and stay competitive in the digital economy. For the first time, enterprises will be able to draw on a digital labor pool of cognitive agents, virtual engineers and virtual administrators in order to automate entire end-to-end processes, from HR and IT, to Finance and Administration. Employees will no longer have to navigate multiple systems but instead channel all their requests and queries through a single cognitively-enabled interface to access a full suite of enterprise services 24-by-7.

Although the average cost of Selling, General and Administrative (SG&A) expenses across industries sits at around 25% of sales1, this can be considerably higher in major industries including Financial Services (41%) and Healthcare (38%). The level of automation made possible by 1Desk(TM) could cut this to a fraction of the cost. At the same time, employee productivity is set to rise sharply as dedicated personal digital support will eliminate the time wasted by filling out cumbersome forms and waiting for routine tasks to be completed.

"1Desk(TM) is the unified service desk that converges the front and back offices. It directly connects business users to the applications that service them, disintermediating large segments of IT and business operations. 1Desk(TM) improves the Net Promoter Scores not only for IT, but for HR, finance, helpdesk, facilities and administrative tasks. The big difference to 1Desk(TM) is that it has cognitive competence so it can understand business users directly, and service their requests through automated digital labor, not by armies of people," said Chetan Dube, CEO of IPsoft.

Uniquely, 1Desk(TM) will be able to target the inefficiencies that lie in processes running across different functions. For example, the comprehensive process knowledge capabilities of Amelia, IPsoft's market-leading cognitive agent embedded in the 1Desk(TM) platform, can act as the glue to unify the implications of policy changes across all supporting enterprise systems by automatically updating intelligent workflows.

In the $6.3 trillion2 race for digital renovation, manual processes have become a stumbling block for operational efficiency and market growth. Static point solutions that automate single steps in the process limit the speed of change that is required to compete with companies that were 'born-digital' as well as traditional competitors that are on a fast track to digital adoption. Through machine learning, 1Desk(TM) facilitates rapid improvement and industrializes a cycle of continuous improvement and learning from every interaction with business users. Exceptions that are managed by human engineers and administrators within 1Desk(TM) are recorded at all times so that a stream of new intelligent automation is generated, speeding up the ability to implement new efficiencies going forward.

Carestream Health, a global provider of medical imaging systems and IT solutions, will be the first Beta customer for 1Desk(TM). "1Desk(TM) introduces AI innovation on a grand scale, opening up the possibility to set a new standard for cognitive-enabled business processes in terms of both speed and quality," said Gerson Benker, Vice President of IT Operations at Carestream. "We are excited at the prospect of employing 1Desk(TM)'s end-to-end automation capabilities within our strategy in order to provide an even better experience for our business users and customers."

The vastly increased automation of business processes enabled by 1Desk(TM) represents a radical shift in the operating model for enterprise organizational models. In the future, the execution of tasks will be predominantly fulfilled by Digital Labor. Human talent will focus on managing and directing the further development of automation. IPsoft facilitates the creation of a Digital Labor Studio within organizations to orchestrate the rapid development of a continuously improving Digital Workforce. This unique hub of digital enablement talent will coordinate the work of automation engineers, data scientists, linguists, business analysts, user-experience designers and system integrators to deliver on the full value of 1Desk(TM).

1Desk(TM) is created on a foundation of market-leading technology. Amelia is widely recognized as being at the forefront of conversational AI platforms and was recently described by industry analyst firm Ovum as being uniquely suitable for enabling entirely new customer channels. IPsoft's autonomic technology has been spearheading transformation at scale for more than 15 years and is noted by research analyst Everest Group as the leader in IT automation.

1  SG&A Benchmarks, Schonfield & Associates 2 IDC Worldwide Semiannual Digital Transformation Spending Guide, May 2017

About IPsoft
IPsoft, the leader in enterprise AI, automates IT and business processes for enterprises across a wide range of industries by deploying Digital Labor. Through its portfolio of world leading autonomic and cognitive solutions, IPsoft provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has 18 offices in 15 countries across the world and serves more than 500 of the world's leading brands directly as well as more than half of the world's largest IT services providers.

Contact
IPsoft
Daniela Zuin, +1 212 708 5521 
Marketing Director, IPsoft
daniela.zuin@ipsoft.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum